Download Sample
Add to CartGlobal Hemostasis and Tissue Sealing Agents Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Topical Hemostats - Active, Mechanical & Flowable, Adhesive & Tissue Sealant - Synthetic Tissue Sealant, Natural Tissue Sealant, and Adhesion Barrier Products.By Material;
Gelatin-Based Topical Hemostats, Collagen-Based Topical Hemostats, ORC-Based Topical Hemostats, and Polysaccharide-Based Topical Hemostats.By Application;
General Surgery, Neurosurgery, Vascular Surgery, Cardiovascular Surgery, and Others.By End-use;
Hospitals, Ambulatory Surgical Centers, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Hemostasis and Tissue Sealing Agents Market (USD Million), 2021 - 2031
In the year 2024, the Global Hemostasis and Tissue Sealing Agents Market was valued at USD 3,608.84 million. The size of this market is expected to increase to USD 5,239.26 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.5%.
The Global Hemostasis and Tissue Sealing Agents Market is witnessing a remarkable surge driven by advancements in surgical techniques, rising surgical procedures across various medical specialties, and an increasing focus on minimizing blood loss during surgeries. Hemostasis and tissue sealing agents play a pivotal role in controlling bleeding and sealing tissues effectively, thereby enhancing patient outcomes and reducing post-operative complications. This market encompasses a wide array of products including hemostats, sealants, and adhesives, catering to diverse surgical needs ranging from cardiovascular and orthopedic surgeries to general and cosmetic procedures.
The global market is the growing demand for minimally invasive surgeries (MIS), where these agents are crucial for achieving effective hemostasis and tissue sealing without the need for extensive incisions. The expanding geriatric population worldwide, coupled with the increasing incidence of chronic diseases necessitating surgical interventions, further propels the demand for these products. Moreover, technological advancements such as the development of advanced biomaterials and innovative delivery systems are fostering market growth by improving the efficacy and ease of application of hemostasis and tissue sealing agents.
Rising healthcare expenditures in both developed and emerging economies, coupled with the growing awareness regarding the benefits of using hemostasis and tissue sealing agents in surgical procedures, are contributing to the market expansion. However, stringent regulatory requirements for product approval and the high cost associated with advanced hemostats and tissue sealants may pose challenges to market players. Nevertheless, strategic initiatives such as mergers and acquisitions, collaborations, and product innovations are expected to drive the market forward, ensuring a promising outlook for the global hemostasis and tissue sealing agents market in the coming years.
Global Hemostasis and Tissue Sealing Agents Market Recent Developments
-
In October 2023, CSL announced that Health Canada has authorized HEMGENIX (etranacogene dezaparvovec), a gene therapy for treating hemophilia B. HEMGENIX is indicated for adults with hemophilia B who need routine prophylaxis to prevent or reduce bleeding episodes. This approval enables the company to commercialize its product in Canada
-
In February 2023, The U.S. FDA has approved Sanofi’s once-weekly Factor VIII replacement therapy, ALTUVIIIO, for both on-demand and prophylactic treatment of hemophilia
Segment Analysis
The Global Hemostasis and Tissue Sealing Agents Market is segmented by Product, Material, Application, and End-use, each focusing on different aspects of the use and types of hemostatic agents and tissue sealants. In the Product segment, the market is categorized into Topical Hemostats and Adhesive & Tissue Sealants. Topical hemostats, including Active, Mechanical, and Flowable types, are commonly used to control bleeding during surgeries by either promoting clotting or physically applying pressure to stop blood flow. Active hemostats contain agents that chemically react to stop bleeding, while Mechanical hemostats provide physical pressure to control blood flow, and Flowable hemostats are easy to apply in various surgical sites. In addition, Adhesive & Tissue Sealants, such as Synthetic Tissue Sealants, Natural Tissue Sealants, and Adhesion Barrier Products, are used to bind tissues together and prevent unwanted adhesions after surgery. These products are essential in a variety of surgical procedures to enhance wound healing and reduce the risk of complications like infections and internal bleeding.
In the Material segment, the market is further divided into different types of hemostats based on their composition, including Gelatin-Based Topical Hemostats, Collagen-Based Topical Hemostats, ORC-Based Topical Hemostats (oxidized regenerated cellulose), and Polysaccharide-Based Topical Hemostats. Gelatin-based hemostats are widely used due to their biocompatibility and ability to form a gel-like consistency to promote clot formation. Collagen-based hemostats are commonly used in surgical applications for their ability to facilitate the natural clotting process and accelerate tissue repair. ORC-based hemostats are favored in surgeries requiring rapid hemostasis and are often used in abdominal and gynecological surgeries. Polysaccharide-based hemostats are derived from natural plant materials and are gaining popularity for their effectiveness in promoting blood clotting, especially in vascular and trauma surgeries. These materials are chosen based on their specific properties, such as ease of application, speed of action, and the type of surgery being performed.
In the Application segment, the market is segmented into key surgical specialties, including General Surgery, Neurosurgery, Vascular Surgery, Cardiovascular Surgery, and Others. General Surgery involves a wide range of procedures where hemostasis agents are crucial for controlling blood loss and promoting healing. In Neurosurgery, the use of hemostatic agents is vital to manage delicate brain surgeries where bleeding must be minimized to prevent complications. Vascular Surgery often requires advanced hemostatic agents to control bleeding in blood vessels and to assist in the repair or grafting of arteries and veins. Cardiovascular Surgery also benefits from hemostasis and tissue sealing products, particularly in heart surgeries such as coronary bypass or valve replacement, where controlling bleeding is critical. The Others category includes specialized surgeries like orthopedic, gastrointestinal, and urological surgeries, where these products are used to ensure optimal outcomes. In the End-use segment, Hospitals, Ambulatory Surgical Centers (ASCs), and Others represent the primary users of hemostasis and tissue sealing products. Hospitals account for the largest market share, as they conduct a wide range of complex surgeries requiring advanced hemostatic and sealing solutions. Ambulatory Surgical Centers are growing in popularity due to the increasing number of outpatient surgeries, where fast and effective hemostasis is crucial for minimizing recovery time and ensuring patient safety. The Others category includes research institutions and emergency medical settings, where these agents are used in trauma care, clinical trials, or specialized procedures. The segmentation of the market into these categories highlights the diverse applications and growing demand for hemostasis and tissue sealing agents across various healthcare settings.
Global Hemostasis and Tissue Sealing Agents Segment Analysis
In this report, the Global Hemostasis and Tissue Sealing Agents Market has been segmented by Product, Material, Application, End Use, and Geography.
Global Hemostasis and Tissue Sealing Agents Market, Segmentation by Product
The Global Hemostasis and Tissue Sealing Agents Market has been segmented by Product into Topical Hemostats - Active, Mechanical & Flowable, Adhesive & Tissue Sealant - Synthetic Tissue Sealant, Natural Tissue Sealant and Adhesion Barrier Products.
The Global Hemostasis and Tissue Sealing Agents Market, segmented by product into topical hemostats and adhesive & tissue sealants, reflects the critical role these products play in modern surgical practices. Topical hemostats encompass a range of formulations designed to control bleeding by promoting clotting or providing mechanical barriers. These products are instrumental in various surgical procedures, ensuring surgeons can effectively manage bleeding, minimize blood loss, and improve patient outcomes. With advancements in material science and formulation techniques, topical hemostats continue to evolve, offering enhanced hemostatic properties and improved patient safety profiles.
Adhesive & tissue sealant products play a crucial role in sealing tissues and promoting wound healing. They provide a reliable method for closing surgical incisions, reducing the risk of post-operative complications such as leakage and infection. Within this segment, a variety of synthetic and natural options are available, each offering unique advantages in terms of adhesion strength, biocompatibility, and degradation profile. As surgical techniques advance and patient expectations rise, the demand for effective adhesive & tissue sealant products is expected to grow, driving innovation and competition in the market.
The segmentation of the Global Hemostasis and Tissue Sealing Agents Market into topical hemostats and adhesive & tissue sealant products underscores the diverse needs of surgeons across different medical specialties. From achieving hemostasis in high-pressure bleeding situations to ensuring secure tissue closure and promoting optimal wound healing, these products play a vital role in modern surgical practices. As healthcare systems worldwide prioritize patient safety, cost-effectiveness, and improved surgical outcomes, the market for hemostasis and tissue sealing agents is poised for sustained growth, driven by innovation, technological advancements, and the expanding scope of surgical interventions.
Global Hemostasis and Tissue Sealing Agents Market, Segmentation by Material
The Global Hemostasis and Tissue Sealing Agents Market has been segmented by Material into Gelatin-Based Topical Hemostats, Collagen-Based Topical Hemostats, ORC-Based Topical Hemostats, and Polysaccharide-Based Topical Hemostats.
The segmentation of the Global Hemostasis and Tissue Sealing Agents Market by material highlights the diverse range of options available to surgeons for achieving hemostasis and tissue sealing in various surgical scenarios. Gelatin-based topical hemostats offer effective hemostatic properties, forming a matrix that promotes platelet aggregation and clot formation at the bleeding site. Collagen-based topical hemostats leverage the natural clotting cascade by providing a scaffold for platelet adhesion and activation, aiding in the formation of stable blood clots. These materials are widely used across different surgical specialties due to their biocompatibility and versatility in managing bleeding.
In addition to gelatin and collagen, ORC-based topical hemostats provide an alternative solution for controlling bleeding by promoting the activation of clotting factors and enhancing platelet aggregation. ORC, or oxidized regenerated cellulose, offers hemostatic properties through its ability to absorb blood and accelerate clot formation, making it particularly useful in situations where rapid hemostasis is essential. Moreover, polysaccharide-based topical hemostats, derived from natural sources such as plant fibers or microbial fermentation, offer biocompatible and absorbable options for achieving hemostasis without the need for human or animal-derived materials.
The segmentation of the Global Hemostasis and Tissue Sealing Agents Market by material reflects ongoing advancements in biomaterials and formulation techniques aimed at improving surgical outcomes and patient safety. Each material category brings its unique set of characteristics, allowing surgeons to tailor hemostasis and tissue sealing strategies to specific patient needs and surgical requirements. As research and development in biomaterial science continue to evolve, the market is expected to witness further innovation in hemostatic and tissue sealing agents, driving the adoption of advanced materials and expanding the scope of surgical interventions.
Global Hemostasis and Tissue Sealing Agents Market, Segmentation by Application
The Global Hemostasis and Tissue Sealing Agents Market has been segmented by Application into General Surgery, Neurosurgery, Vascular Surgery, Cardiovascular Surgery, and Others.
The Global Hemostasis and Tissue Sealing Agents Market is segmented by Application into several key areas, including General Surgery, Neurosurgery, Vascular Surgery, Cardiovascular Surgery, and Others, each reflecting the specialized use of hemostasis and tissue sealing agents in different surgical fields. These agents are critical in managing bleeding, promoting tissue repair, and facilitating healing during and after surgery.
In General Surgery, hemostasis and tissue sealing agents are used to control bleeding during a wide range of procedures. These agents are commonly employed in surgeries such as abdominal operations, gallbladder removals, or appendectomies. Hemostatic agents play a vital role in preventing excessive blood loss and promoting wound healing by sealing tissues or blood vessels. The increasing number of general surgeries being performed globally drives the demand for these agents, contributing to their significant market share.
Neurosurgery, Vascular Surgery, and Cardiovascular Surgery represent more specialized applications of hemostasis and tissue sealing agents. In Neurosurgery, these agents are essential for managing bleeding in delicate and critical brain surgeries, where controlling bleeding is crucial for patient safety and surgical success. Similarly, in Vascular Surgery, these agents are used to seal blood vessels and tissues to prevent leakage during procedures such as angioplasty, bypass surgeries, and other interventions. In Cardiovascular Surgery, including coronary artery bypass grafting (CABG) and heart valve surgeries, hemostasis and tissue sealing agents are crucial for controlling blood flow and ensuring the success of the procedure. These surgeries often involve complex procedures with significant risks of bleeding, making the use of effective sealing agents vital for patient outcomes. The Others category includes other specialized surgeries, such as orthopedic, gynecological, and thoracic surgeries, where hemostasis and tissue sealing agents are used to control bleeding and improve surgical outcomes. These agents are essential in minimizing blood loss and enhancing healing across various surgical disciplines, contributing to the overall growth of the market.
Global Hemostasis and Tissue Sealing Agents Market, Segmentation by End-use
The Global Hemostasis and Tissue Sealing Agents Market has been segmented by End-use into Hospitals, Ambulatory Surgical Centers, and Others.
The Global Hemostasis and Tissue Sealing Agents Market is segmented by End-use into Hospitals, Ambulatory Surgical Centers (ASCs), and Others, each playing a significant role in the adoption and utilization of these agents in clinical practice. These segments reflect the diverse settings where hemostasis and tissue sealing agents are used to control bleeding and promote tissue repair during and after surgeries.
Hospitals are the largest end-use segment, as they perform a wide variety of surgeries, including complex and high-risk procedures such as cardiovascular, neurosurgery, and trauma surgeries. Hemostasis and tissue sealing agents are crucial in hospitals for controlling bleeding, reducing complications, and promoting faster healing in patients undergoing surgery. Given the extensive resources, advanced equipment, and a large number of specialized surgeries performed in hospitals, these settings require a constant supply of hemostatic agents and sealing technologies to support the surgical teams and improve patient outcomes.
Ambulatory Surgical Centers (ASCs) are another significant end-use segment. ASCs are outpatient surgical facilities where a wide range of elective and minimally invasive procedures are performed. These centers often focus on procedures that require quicker recovery times, such as orthopedic, ENT, and dermatological surgeries. Hemostasis and tissue sealing agents are particularly valuable in these settings to minimize the risk of bleeding and ensure rapid recovery for patients. The demand for these agents in ASCs has increased due to the rising trend of outpatient surgeries, where efficiency and patient safety are key priorities.
The Others category encompasses a range of other healthcare settings, such as specialized clinics, research institutions, and military or emergency medical settings, where hemostasis and tissue sealing agents are utilized for specific surgical or medical interventions. These settings may use these agents for a variety of purposes, from clinical trials and research studies to trauma care in emergency departments or on the battlefield. The growing versatility and adoption of hemostasis and tissue sealing agents in diverse healthcare environments further fuel the market's expansion across different end-use categories.
Global Hemostasis and Tissue Sealing Agents Market, Segmentation by Geography
In this report, the Global Hemostasis and Tissue Sealing Agents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Hemostasis and Tissue Sealing Agents Market Share (%), by Geographical Region, 2024
The Global Hemostasis and Tissue Sealing Agents Market by geography into five distinct regions provides valuable insights into regional trends, market dynamics, and opportunities for market players. North America, as one of the largest markets, exhibits robust demand driven by advanced healthcare infrastructure, high surgical volumes, and increasing adoption of innovative surgical techniques. Moreover, stringent regulatory standards and a strong emphasis on patient safety contribute to the widespread utilization of hemostasis and tissue sealing agents in surgical procedures across various medical specialties.
In Europe, the market for hemostasis and tissue sealing agents is characterized by a mature healthcare landscape, substantial investments in research and development, and a growing geriatric population. These factors, coupled with rising healthcare expenditure and a focus on minimizing surgical complications, drive market growth in the region. Additionally, increasing awareness among healthcare professionals regarding the benefits of using advanced hemostats and tissue sealants further propels market expansion in Europe.
In the Asia Pacific region, the hemostasis and tissue sealing agents market are witnessing rapid growth fueled by expanding healthcare infrastructure, rising surgical procedures, and growing medical tourism. Countries such as China, India, and Japan are emerging as key markets due to their large patient populations, increasing healthcare expenditure, and efforts to improve access to quality healthcare services. Moreover, strategic collaborations between global market players and local distributors, along with initiatives to enhance healthcare affordability and accessibility, are expected to drive market penetration and foster market growth in the Asia Pacific region.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Hemostasis and Tissue Sealing Agents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Surgical Advancements
- Rising Surgical Procedures
-
Minimally Invasive Surgery (MIS) - Minimally Invasive Surgery (MIS) has revolutionized modern surgical practices by offering patients less invasive alternatives to traditional open surgeries. Unlike conventional procedures that require large incisions, MIS utilizes advanced surgical techniques and specialized instruments to access internal organs through small incisions. This approach minimizes trauma to surrounding tissues, resulting in reduced post-operative pain, shorter hospital stays, faster recovery times, and lower rates of complications. MIS is widely employed across various medical specialties, including gynecology, urology, orthopedics, and general surgery, owing to its numerous patient benefits and improved surgical outcomes.
One of the key advantages of MIS is its ability to enhance patient quality of life by minimizing surgical trauma and reducing the physical and psychological burden associated with traditional open surgeries. By allowing for smaller incisions and precise surgical maneuvers, MIS offers patients faster return to normal activities and improved cosmetic outcomes. Additionally, MIS often results in less blood loss during surgery, reducing the need for blood transfusions and lowering the risk of complications such as infections and wound healing problems. These benefits not only improve patient satisfaction but also contribute to healthcare cost savings by reducing hospitalization expenses and post-operative care requirements.
The continued advancements in technology and surgical techniques are driving the expansion of MIS procedures and improving their efficacy and safety profiles. Innovations such as robotic-assisted surgery, laparoscopy, and endoscopy enable surgeons to perform increasingly complex procedures with greater precision and control. As a result, the adoption of MIS is expected to continue growing globally, driven by factors such as increasing patient demand for minimally invasive treatment options, advancements in medical device technology, and the expanding expertise of healthcare professionals in performing minimally invasive procedures.
Restraints
- Regulatory Challenges
- High Costs
-
Limited Reimbursement Policies - Limited reimbursement policies pose a significant challenge to both healthcare providers and patients seeking access to essential medical treatments and procedures. Reimbursement policies, determined by government healthcare systems, private insurance companies, and other payers, dictate the extent to which medical expenses are covered. In the context of limited reimbursement for certain treatments or procedures, patients may face financial barriers to accessing necessary healthcare services, leading to disparities in healthcare access and outcomes. Limited reimbursement policies often result from budget constraints, cost containment efforts, and concerns about the cost-effectiveness of specific treatments relative to their perceived benefits.
For healthcare providers, limited reimbursement policies can impact the financial viability of offering certain services, particularly those with high upfront costs or low reimbursement rates. This can affect the availability of medical procedures and treatments within healthcare facilities, limiting patient access to potentially life-saving interventions. Additionally, healthcare providers may face challenges in maintaining quality of care and investing in advanced technologies and treatments when faced with constrained reimbursement policies. Consequently, there may be a reluctance among healthcare providers to offer certain services or invest in innovative treatments due to concerns about financial sustainability.
Patients are directly impacted by limited reimbursement policies, as they may be required to bear a greater financial burden for healthcare services not fully covered by insurance or government healthcare programs. This can lead to delays in seeking necessary medical care, reluctance to undergo recommended treatments, or financial hardship for individuals and families. Limited reimbursement policies can exacerbate healthcare inequalities, particularly for vulnerable populations with limited financial resources or access to comprehensive insurance coverage. Addressing these challenges requires collaborative efforts among policymakers, healthcare providers, insurers, and patient advocacy groups to ensure equitable access to affordable and high-quality healthcare services for all individuals.
Opportunities
- Product Innovations
- Strategic Partnerships
-
Increasing Healthcare Expenditure - Increasing healthcare expenditure is a multifaceted phenomenon with profound implications for healthcare systems, economies, and societies worldwide. As populations grow, age, and experience shifts in disease prevalence, demand for healthcare services escalates, leading to rising healthcare expenditures. Factors such as advancements in medical technology, expanding treatment options, and increasing expectations for quality care further drive up healthcare costs. Moreover, as standards of living improve and individuals seek better access to healthcare services, there is a natural inclination towards increased healthcare spending to meet these demands.
Healthcare expenditure encompasses various components, including spending on medical facilities, personnel, pharmaceuticals, medical devices, and administrative costs. As healthcare becomes more complex and specialized, costs associated with diagnostic and treatment modalities continue to climb. Additionally, factors such as inflation, labor market dynamics, and regulatory requirements contribute to the overall escalation of healthcare expenditure. While increased healthcare spending reflects society's commitment to improving health outcomes and access to care, it also presents challenges related to affordability, sustainability, and resource allocation within healthcare systems.
Addressing the implications of increasing healthcare expenditure requires a comprehensive approach that balances the need for healthcare innovation and accessibility with cost containment measures. Policymakers, healthcare providers, insurers, and stakeholders must collaborate to implement strategies aimed at optimizing healthcare spending while maintaining or improving quality of care. This may involve initiatives such as value-based healthcare delivery, preventive medicine programs, adoption of cost-effective technologies, and promoting greater transparency in healthcare pricing and reimbursement practices. By fostering efficiency, innovation, and accountability within healthcare systems, stakeholders can navigate the complexities of increasing healthcare expenditure and work towards achieving sustainable and equitable healthcare for all.
Competitive Landscape Analysis
Key players in Global Hemostasis and Tissue Sealing Agents Market include:
- Johnson & Johnson
- CryoLife Inc
- Advance Medical Solution (AMS) Group Plc
- Cohera Medical Inc
- Integra Life Sciences Corporation
- Pfizer Inc
- C R Bard Inc
- Cohesion Technologies Inc
- HyperBranch Medical Technology
- Biomet Inc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Material
- Market Snapshot, By Application
- Market Snapshot, By End-use
- Market Snapshot, By Region
- Global Hemostasis and Tissue Sealing Agents Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Surgical Advancements
- Rising Surgical Procedures
- Minimally Invasive Surgery (MIS)
- Restraints
- Regulatory Challenges
- High Costs
- Limited Reimbursement Policies
- Opportunities
- Product Innovations
- Strategic Partnerships
- Increasing Healthcare Expenditure
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Hemostasis and Tissue Sealing Agents Market, By Product, 2021 - 2031 (USD Million)
- Topical Hemostats
- Active
- Mechanical
- Flowable
- Adhesive & Tissue Sealant
- Synthetic Tissue Sealant
- Natural Tissue Sealant
- Adhesion Barrier Products
- Topical Hemostats
- Global Hemostasis and Tissue Sealing Agents Market, By Material, 2021 - 2031 (USD Million)
- Gelatin-Based Topical Hemostats
- Collagen-Based Topical Hemostats
- ORC-Based Topical Hemostats
- Polysaccharide-Based Topical Hemostats
- Global Hemostasis and Tissue Sealing Agents Market, By Application, 2021 - 2031 (USD Million)
- General Surgery
- Neurosurgery
- Vascular Surgery
- Cardiovascular Surgery
- Others
- Global Hemostasis and Tissue Sealing Agents Market, By End-use, 2021 - 2031 (USD Million)
- Hospitals
- Ambulatory Surgical Centers
- Others
- Global Hemostasis and Tissue Sealing Agents Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Hemostasis and Tissue Sealing Agents Market, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Johnson & Johnson
- CryoLife Inc
- Advance Medical Solution (AMS) Group Plc
- Cohera Medical Inc
- Integra Life Sciences Corporation
- Pfizer Inc
- C R Bard Inc
- Cohesion Technologies Inc
- HyperBranch Medical Technology
- Biomet Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market